Drug Trial Radar · NCT00373685
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,067
Actual
Start
Oct 2006
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.
Conditions
- Osteoarthritis
Interventions
CelecoxibDrug
open-label
Any commercially available NSAID with the indication for osteoarthritisDrug
dosing as per USPI label related to the chosen commercially marketed NSAID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)Time frame: Baseline through week 24 or Early Termination (ET)
Locations
777 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Abbeville, Alabama
Pfizer Investigational Site
Alexander City, Alabama
Pfizer Investigational Site
Bay Minette, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Cullman, Alabama
Pfizer Investigational Site
Dothan, Alabama
Pfizer Investigational Site
Dothan, Alabama
Pfizer Investigational Site
Geneva, Alabama
Pfizer Investigational Site
Gulf Shores, Alabama
Pfizer Investigational Site
Guntersville, Alabama
Pfizer Investigational Site
Huntsville, Alabama
Pfizer Investigational Site
Huntsville, Alabama
Pfizer Investigational Site
Jacksonville, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Muscle Shoals, Alabama
Pfizer Investigational Site
Ozark, Alabama
Pfizer Investigational Site
Pell City, Alabama
Pfizer Investigational Site
Tallassee, Alabama
Pfizer Investigational Site
Chandler, Arizona
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Green Valley, Arizona
Pfizer Investigational Site
Mesa, Arizona
Pfizer Investigational Site
Mesa, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Sierra Vista, Arizona
Pfizer Investigational Site
Sun Lakes, Arizona
Pfizer Investigational Site
Tempe, Arizona
Pfizer Investigational Site
Tempe, Arizona
Pfizer Investigational Site
Tucson, Arizona
Showing 40 of 777 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.